A new COVID-19 vaccine is on its way to hit the market. Designed by the French pharmaceutical company Valneva, this vaccine is currently working on its phase 3 trial and is expected to be completed by autumn of 2021. This vaccine is catching attention as it uses the traditional vaccine technology, which is said to create a stronger immune response to the coronavirus. Because it creates a traditional immune response, it is expected to be more effective against variants - some scientists even calling it "variant proof."
This vaccine technology is similar to those against poliovirus and the yearly flu vaccine - essentially using an inactivated version of the virus. Valneva has recruited a group from the UK for the clinical trial and has so far seen no serious or concerning side effects. Countries including France, the UK, and Australia have already shown serious interest in preordering this new vaccine.
Image Credit: Valneva